Drug targets for deadly Nipah virus identified by Indian Researchers from IISER

Taking the fight against the dreaded Nipah disease to a new level, researchers at Pune-based Indian Institute of Science Education and Research (IISER) have developed drug targets for the virus that causes the disease, using the molecular modeling approach.
Also read>>>Nipah Virus Is The Next Emerging Threat To Healthcare Says Experts
Nipah virus outbreaks have very high mortality rates, over 70% in Southeast Asia. The virus spreads via bodily secretions of bats, pigs and infected individuals. It was first detected in human populations in 1998 in Malaysia, then made its way into the Indian subcontinent with outbreaks in Bangladesh and India a few years later.
The Nipah virus is an RNA virus. In other words, its genetic material is RNA surrounded by a protein envelope. Like all viruses, it makes copies of itself and propagates by invading and hijacking the machinery of the host cell, destroying it in the process. The virus’ protein envelope is made of six proteins, and its RNA produces three more proteins to defend itself from the responses of the host cells.

The researchers considered all nine proteins as potential therapeutic targets. They used the genetic sequence of a strain of the Nipah virus from Malaysia and constructed computer models of the protein structures. They then used the models to design molecules that could interfere with the molecular mechanisms of the viral proteins to kill or at least disable it.

They also compared the genetic sequences of 15 strains of viruses from across Bangladesh, Malaysia and India and found that those parts of the proteins that would directly interact with the drug molecules were not effectively different across the strains.

The researchers have put out various details of their work including the structures of the molecules on the website of their Institute for use by other researchers to take up further studies.

#buttons=(Accept !) #days=(20)

Our website uses cookies to enhance your experience. Learn More
Accept !
To Top